satri-cel

CARsgen's satri-cel joins China's commercial insurance drug list

Image
CARsgen's satri-cel joins China's commercial insurance drug list

SHANGHAI -- November 19, 2026 -- China's National Healthcare Security Administration (NHSA) and the Ministry of Human Resources and Social Security (MOHRSS) have added CARsgen's CAR T-cell therapy satri-cel to the 2026 Commercial Health Insurance Innovative Drug List (CHIIDL). The listing comes about five months after the National Medical Products Administration approved the product in June 2026.

Satri-cel (satricabtagene autoleucel, code CT041) targets Claudin18.2. The listed indication is Claudin18.2-positive, HER2-negative advanced gastric or gastroesophageal junction adenocarcinoma in patients who have failed at least two prior lines of therapy. CARsgen trades in Hong Kong under stock code 2171.HK.